Indication intelligence, analysis and sector perception

Bellicum Pharmaceuticals (BLCM) FDA has lifted the clinical hold

January 28, 2021 6:22pm

On patient enrollment and dosing in an ongoing P1/2 dose-escalation clinical trial evaluating BPX-601 and rimiducid in patients with previously treated metastatic pancreatic or prostate cancer.

BLCM closed down -$0.04 to $3.84 and has a positive +$2.12 or +55.47% to $5.97

BLCM has satisfactorily addressed all clinical hold issues and may now resume enrollment without modification to the current study protocol. The company plans to work with clinical investigators to resume patient enrollment.

BPX-601 is the first GoCAR-T® product candidate, incorporates iMC, BLCM’s inducible co-activation domain.

iMC (inducible MyD88/CD40) is designed to provide a powerful boost to T cell proliferation and persistence, production of immunomodulatory cytokines and enable the CAR-T to override key immune inhibitory mechanisms, including PD-1 and TGF-beta. BPX-601 is being evaluated as a treatment for pancreatic and prostate tumors expressing prostate stem cell antigen (PSCA).

35 companies, 1 interpreter!

Insight, foresight and recommendation

What's Happening Today

1 hour 33 min ago
RegMed Investors’ (RMi) pre-open: No single indicator is a guide to sector share pricing conditions

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.